1. Home
  2. OCX vs PMN Comparison

OCX vs PMN Comparison

Compare OCX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCX
  • PMN
  • Stock Information
  • Founded
  • OCX 2009
  • PMN 2004
  • Country
  • OCX United States
  • PMN Canada
  • Employees
  • OCX N/A
  • PMN N/A
  • Industry
  • OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • OCX Health Care
  • PMN Health Care
  • Exchange
  • OCX Nasdaq
  • PMN Nasdaq
  • Market Cap
  • OCX 35.1M
  • PMN 29.8M
  • IPO Year
  • OCX N/A
  • PMN N/A
  • Fundamental
  • Price
  • OCX $2.74
  • PMN $0.90
  • Analyst Decision
  • OCX Buy
  • PMN
  • Analyst Count
  • OCX 3
  • PMN 0
  • Target Price
  • OCX $4.42
  • PMN N/A
  • AVG Volume (30 Days)
  • OCX 88.9K
  • PMN 47.2K
  • Earning Date
  • OCX 04-11-2025
  • PMN 03-31-2025
  • Dividend Yield
  • OCX N/A
  • PMN N/A
  • EPS Growth
  • OCX N/A
  • PMN N/A
  • EPS
  • OCX N/A
  • PMN N/A
  • Revenue
  • OCX $709,000.00
  • PMN N/A
  • Revenue This Year
  • OCX N/A
  • PMN N/A
  • Revenue Next Year
  • OCX $106.34
  • PMN N/A
  • P/E Ratio
  • OCX N/A
  • PMN N/A
  • Revenue Growth
  • OCX N/A
  • PMN N/A
  • 52 Week Low
  • OCX $1.92
  • PMN $0.83
  • 52 Week High
  • OCX $3.48
  • PMN $2.61
  • Technical
  • Relative Strength Index (RSI)
  • OCX 69.99
  • PMN 50.80
  • Support Level
  • OCX $2.21
  • PMN $0.90
  • Resistance Level
  • OCX $2.80
  • PMN $1.03
  • Average True Range (ATR)
  • OCX 0.22
  • PMN 0.05
  • MACD
  • OCX 0.08
  • PMN 0.00
  • Stochastic Oscillator
  • OCX 89.95
  • PMN 40.00

About OCX Oncocyte Corporation

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: